References

Cancer statistics, 2025

10.3322/caac.21871 · 2025 · External reference

Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer

10.1056/nejmoa1810858 · 2018 · External reference

FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy

10.1158/1078-0432.ccr-15-0887 · 2015 · External reference

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

10.1038/s41571-018-0055-6 · 2018 · External reference

Clinical and translational advances in ovarian cancer therapy

10.1038/s43018-023-00617-9 · 2023 · External reference

Understanding and overcoming resistance to PARP inhibitors in cancer therapy

10.1038/s41571-021-00532-x · 2021 · External reference

Tumour acidosis: from the passenger to the driver’s seat

10.1038/nrc.2017.77 · 2017 · External reference

Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach

10.1016/j.drup.2015.08.004 · 2015 · External reference

Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells

10.1158/1078-0432.ccr-20-4391 · 2021 · External reference

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation

10.1182/blood.2022019306 · 2025 · External reference

Protein lysine acetylation by p300/CBP

10.1021/cr500452k · 2015 · External reference

Preclinical development and characterization of IACS-16559, a dual bromodomain inhibitor of CBP/EP300, and its potential in AML subtypes

10.1158/1538-7445.am2025-447 · 2025 · External reference

TT125-802, a highly selective bromodomain inhibitor of CBP/p300, in patients with advanced solid tumors: an update on the phase I study

10.1016/j.ejca.2024.114644 · 2024 · External reference

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies

10.1016/j.ccell.2023.11.001 · 2023 · External reference

Targeting the p300/CBP axis in lethal prostate cancer

10.1158/2159-8290.cd-20-0751 · 2021 · External reference

Mouse ovarian cancer models recapitulate the human tumor microenvironment and patient response to treatment

10.1016/j.celrep.2019.12.034 · 2020 · External reference

Development of a syngeneic mouse model for events related to ovarian cancer

10.1093/carcin/21.4.585 · 2000 · External reference

Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers

10.1158/0008-5472.can-13-2247 · 2014 · External reference

BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer

10.1016/j.celrep.2017.11.095 · 2017 · External reference

The SETDB1-TRIM28 complex suppresses antitumor immunity

10.1158/2326-6066.cir-21-0754 · 2021 · External reference

MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens

10.1186/s13059-014-0554-4 · 2014 · External reference

m6A-independent genome-wide METTL3 and METTL14 redistribution drives the senescence-associated secretory phenotype

10.1038/s41556-021-00656-3 · 2021 · External reference

Toward better understanding of artifacts in variant calling from high-coverage samples

10.1093/bioinformatics/btu356 · 2014 · External reference

The Sequence Alignment/Map format and SAMtools

10.1093/bioinformatics/btp352 · 2009 · External reference

deepTools2: a next generation web server for deep-sequencing data analysis

10.1093/nar/gkw257 · 2016 · External reference

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

10.1186/s13059-014-0550-8 · 2014 · External reference

RPPA SPACE: an R package for normalization and quantitation of Reverse-Phase Protein Array data

10.1093/bioinformatics/btac665 · 2022 · External reference

A pan-cancer proteomic perspective on The Cancer Genome Atlas

10.1038/ncomms4887 · 2014 · External reference

MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification

10.1038/nbt.1511 · 2008 · External reference

Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN

10.1038/nature24023 · 2017 · External reference

Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling

10.7150/thno.26627 · 2018 · External reference

Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells

2000 · External reference

Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients

10.1186/s12967-022-03763-3 · 2022 · External reference

Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells

10.1016/j.semcancer.2018.10.002 · 2018 · External reference

Dysregulated pH: a perfect storm for cancer progression

10.1038/nrc3110 · 2011 · External reference

MRI of the tumor microenvironment

10.1002/jmri.10181 · 2002 · External reference

Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate

10.1038/nature07017 · 2008 · External reference

PARP inhibitors: synthetic lethality in the clinic

10.1126/science.aam7344 · 2017 · External reference

PARPi-FL-a fluorescent PARP1 inhibitor for glioblastoma imaging

10.1016/j.neo.2014.05.005 · 2014 · External reference

Enhancement of chemotherapy by manipulation of tumour pH

10.1038/sj.bjc.6690455 · 1999 · External reference

Acid suspends the circadian clock in hypoxia through inhibition of mTOR

10.1016/j.cell.2018.05.009 · 2018 · External reference

The multifaceted roles of PARP1 in DNA repair and chromatin remodelling

10.1038/nrm.2017.53 · 2017 · External reference

Targeting the DNA repair pathway in Ewing sarcoma

10.1016/j.celrep.2014.09.028 · 2014 · External reference

Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression

10.1158/1541-7786.mcr-19-1057 · 2020 · External reference

ATF6-mediated signaling contributes to PARP inhibitor resistance in ovarian cancer

10.1158/1541-7786.mcr-22-0102 · 2023 · External reference

Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies

10.1126/sciadv.aav4340 · 2019 · External reference

The transcriptional coactivators p300 and CBP are histone acetyltransferases

10.1016/s0092-8674(00)82001-2 · 1996 · External reference

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

10.1038/nature24028 · 2017 · External reference

Current development of CBP/p300 inhibitors in the last decade

10.1016/j.ejmech.2020.112861 · 2021 · External reference

Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper

10.1158/1078-0432.ccr-22-0301 · 2022 · External reference

Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains

10.1021/ja412434f · 2014 · External reference

BMP2-activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity

10.1074/jbc.m110.142307 · 2010 · External reference

ERK2-mediated C-terminal serine phosphorylation of p300 is vital to the regulation of epidermal growth factor-induced keratin 16 gene expression

10.1074/jbc.m700264200 · 2007 · External reference

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

10.1038/s41416-024-02745-0 · 2024 · External reference

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

10.1038/s41467-020-17127-2 · 2020 · External reference

An integrated encyclopedia of DNA elements in the human genome

10.1038/nature11247 · 2012 · External reference

Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription

10.1074/jbc.m507553200 · 2005 · External reference

PARP inhibition: PARP1 and beyond

10.1038/nrc2812 · 2010 · External reference

Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer

10.1126/sciadv.adf7195 · 2023 · External reference

How protons pave the way to aggressive cancers

10.1038/s41568-023-00628-9 · 2023 · External reference

Proton export upregulates aerobic glycolysis

10.1186/s12915-022-01340-0 · 2022 · External reference

Regulation of inflammatory responses by pH-dependent transcriptional condensates

10.1016/j.cell.2025.06.033 · 2025 · External reference

pH and drug resistance in tumors

10.1054/drup.2000.0119 · 2000 · External reference

Drug resistance and cellular adaptation to tumor acidic pH microenvironment

10.1021/mp200292c · 2011 · External reference

Lactic acid and an acidic tumor microenvironment suppress anticancer immunity

10.3390/ijms21218363 · 2020 · External reference

Association between pH regulation of the tumor microenvironment and immunological state

10.3389/fonc.2023.1175563 · 2023 · External reference

PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness

10.1158/0008-5472.can-18-1003 · 2019 · External reference

Tumor pH and metastasis: a malignant process beyond hypoxia

10.1007/s10555-018-09777-y · 2019 · External reference

The transcriptional co-activators CBP and p300 are activated via phenylephrine through the p42/p44 MAPK cascade

10.1074/jbc.m104626200 · 2002 · External reference

Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

10.1126/scitranslmed.aal5148 · 2017 · External reference

Trapping of PARP1 and PARP2 by clinical PARP inhibitors

10.1158/0008-5472.can-12-2753 · 2012 · External reference

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

10.1126/scitranslmed.aaf9246 · 2016 · External reference

978P Clinical activity of TT125-802, a highly selective bromodomain inhibitor of CBP/p300, in advanced solid tumors: update on the ongoing phase I study

10.1016/j.annonc.2025.08.1547 · 2025 · External reference

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): a PARP1-DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs

10.1021/acs.jmedchem.1c01012 · 2021 · External reference

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

10.1186/s13073-024-01370-z · 2024 · External reference